Axogen Inc vs Hewlett Packard Enterprise Co — how do they compare? Axogen Inc trades at $49.1 (market cap $2.61B), while Hewlett Packard Enterprise Co trades at $57.15 (market cap $72.01B). The key difference: Hewlett Packard Enterprise Co is far larger — about 27.6× Axogen Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | HPE | |
|---|---|---|
Market Cap | $2.61B | $72.01B |
Sector | Technology | Technology |
52-Week High | $48.48 | $56.14 |
52-Week Low | $14.16 | $20.01 |
Enterprise Value | $2.52B | $87.96B |
Dividend Yield | — | 1.05% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.
The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.
HPE stock trades at $56.32, up 3.02% with strong momentum following recent analyst upgrades. The company shows robust earnings beats in recent quarters with Q1 2026 EPS of $0.79 beating expectations of $0.535. Technical indicators suggest bullish momentum while fundamentals show revenue growth to $34.3B in 2025, though net income declined significantly to $57M. Recent Morgan Stanley upgrade highlights AI infrastructure strength.
Outlook remains positive with AI-driven growth potential, though elevated P/E ratio of 50.82 warrants caution. Key risks include competitive pressures in server markets and execution challenges. Analyst consensus price target of $69.81 offers 24% upside potential from current levels, supported by institutional buying interest.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →